Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Trial details
- Registry ID
- NCT01613118
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as Sparsentan
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental GlomerulosclerosisNCT01613118 | TVTX | Phase 2 | Completed | 2016-06Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |